Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach
- PMID: 34954746
- DOI: 10.1097/ADM.0000000000000945
Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach
Abstract
Low dose buprenorphine initiation, is an alternative method of initiating buprenorphine in which the starting dose is very low and gradually increased to therapeutic levels over a period of days. This method takes advantage of slow displacement of the full opioid agonist from mu-opioid receptors, avoiding the need for a person with opioid use disorder to experience opioid withdrawal symptoms before initiating buprenorphine, while also minimizing the risk of precipitated opioid withdrawal. With this initiation method, full opioid agonists can be continued as buprenorphine is initiated, expanding the population to which buprenorphine can be offered. To date, the literature on low dose initiation is primarily case-based but rapidly growing. While evidence emerges, guidance for the use of low dose initiation is clearly desired and urgently needed in the context of an increasingly risky and contaminated opioid drug supply, particularly with high potency synthetic opioids, driving overdose deaths. Despite limited evidence, several principles to guide low dose initiation have been identified including: (1) choosing the appropriate clinical situation, (2) initiating at a low buprenorphine dose, (3) titrating the buprenorphine dose gradually, (4) continuing the full opioid agonist even if it is nonmedical, (5) communicating clearly with frequent monitoring, (6) pausing or delaying buprenorphine dose changes if opioid withdrawal symptoms occur, and (7) prioritizing care coordination. We review a practical approach to low dose initiation in hospital-based and outpatient settings guided by the current evidence.
Copyright © 2021 American Society of Addiction Medicine.
Conflict of interest statement
The authors report no conflicts of interest.
References
-
- Friedman J, Mann NC, Hansen H, et al. Racial/ethnic, social, and geographic trends in overdose-associated cardiac arrests observed by US emergency medical services during the COVID-19 pandemic. JAMA Psychiatry . 2021;78(8):886–895.
-
- Shover CL, Falasinnu TO, Dwyer CL, et al. Steep increases in fentanyl-related mortality west of the Mississippi River: recent evidence from county and state surveillance. Drug Alcohol Depend . 2020;216:108314. DOI:10.1016/j.drugalcdep.2020.108314 . - DOI
-
- Centers for Disease Control and Prevention. “Overdose Deaths Accelerating during COVID-19” Press release December 17 2020. Available at: https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html . Accessed July 28 2021.
-
- Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder. Fed Regist . 2021;86(80):22439–22440.
-
- Substance Abuse, Mental Health Services Administration. Medications for Opioid Use Disorder. In: Treatment Improvement Protocol (TIP) Series 63 Publication No. PEP21-02-01-002 . Rockville, MD: Substance Abuse and Mental Health Services Administration; 2021. ES-12.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials